Outcome of consolidation cohorts
Cohort . | Treatment . | No. . | ANC to 1.0 × 109/L, d median (range) . | Platelets to 100 × 109/L, d median (range) . | Grade 3 or 4 hepatotoxicity . | Deaths . |
|---|---|---|---|---|---|---|
| 7 | MACE and 3 mg/m2 GO | 18 | 27.5 (17-55) | 45 (19-70) | 3 | 2 |
| 8 | HidAC and 3 mg/m2 GO | 13 | 28.5 (21-51) | 45 (21-59) | 0 | 0 |
| 9 | Course 1 with 3 mg/m2 GO and Course 3 (either MACE or HidAC) with 3 mg/m2 GO | 23 | 28 (17-55) | 44.5 (19-70) | 1 | 0 |
Cohort . | Treatment . | No. . | ANC to 1.0 × 109/L, d median (range) . | Platelets to 100 × 109/L, d median (range) . | Grade 3 or 4 hepatotoxicity . | Deaths . |
|---|---|---|---|---|---|---|
| 7 | MACE and 3 mg/m2 GO | 18 | 27.5 (17-55) | 45 (19-70) | 3 | 2 |
| 8 | HidAC and 3 mg/m2 GO | 13 | 28.5 (21-51) | 45 (21-59) | 0 | 0 |
| 9 | Course 1 with 3 mg/m2 GO and Course 3 (either MACE or HidAC) with 3 mg/m2 GO | 23 | 28 (17-55) | 44.5 (19-70) | 1 | 0 |